FDA Reviews Amgen's Video for VECTIBIX Injection
The FDA's Office of Prescription Drug Promotion determined that a submitted video for Amgen's VECTIBIX injection was false or misleading.
Stocks · News reference
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amgen Announces Webcast for 2026 Third Quarter Financial Results
Amgen has scheduled a webcast to discuss its financial results for the third quarter of 2026.
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight
The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.
Regeneron and Amgen Narrow Scope of Eylea Biosimilar Lawsuit
Regeneron Pharmaceuticals and Amgen have reached an agreement to narrow the scope of their ongoing legal dispute regarding Eylea biosimilars.
Baidu Confirms Departure of Vice President Wu Tian
Baidu has officially confirmed that Wu Tian, a Vice President and Deputy Dean of the Baidu Research Institute, has concluded her tenure at the company.
Baidu and Other Leading Internet Firms Sign Self-Discipline Convention to Regulate AI Marketing
Baidu and several other major Chinese internet companies have signed a self-discipline convention in Beijing to regulate the use of AI in commercial promotions and live-streaming marketing.